FIELD: medicine; pharmaceutics.
SUBSTANCE: present invention relates to pharmaceutical compositions suitable for parenteral administration to humans. In particular, the present invention relates to isotonic pharmaceutical compositions of a double GLP1/2 agonist for parenteral administration.
EFFECT: compositions have improved chemical stability.
30 cl, 41 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
| GLP-1/GLP-2 DUAL AGONISTS | 2017 |
|
RU2756011C2 |
| NOVEL ANALOGUES OF GLUCAGON-LIKE PEPTIDE, COMPOSITION AND METHOD OF USE | 2010 |
|
RU2557301C2 |
| STABLE PREPARATIONS OF INSULIN PEPTIDES | 2005 |
|
RU2413530C2 |
| PEPTIDE COMPOSITION CONTAINING PROPYLENE GLYCOL OPTIMAL FOR MANUFACTURING AND APPLICATION IN INJECTION DEVICES | 2004 |
|
RU2421238C2 |
| STABILISED PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE | 2004 |
|
RU2421236C2 |
| LIQUID FORMULATIONS OF GLUCAGON ANALOGUES | 2021 |
|
RU2819934C1 |
| LIQUID COMPOSITION OF LONG-ACTING INSULIN AND INSULINOTROPIC PEPTIDE | 2013 |
|
RU2643766C2 |
| NEW DERIVATIVES OF OXYNTOMODULIN AND PHARMACEUTICAL COMPOSITION FOR TREATING OBESITY | 2012 |
|
RU2612906C2 |
| PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON | 2016 |
|
RU2719482C2 |
